ADMA Biologics
ADMA
18 hedge funds and large institutions have $48M invested in ADMA Biologics in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 1 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.82% less ownership
Funds ownership: 73.54% → 72.71% (-0.82%)
5% less funds holding
Funds holding: 19 → 18 (-1)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
89% less capital inflows, than outflows
Capital inflows: $74K | Capital outflows: $684K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$50.8K |
| 2 |
PCM
Prelude Capital Management
New York
|
+$21.1K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.06K |
| 4 |
BlackRock Fund Advisors
San Francisco,
California
|
+$1.01K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IHM
Iguana Healthcare Management
New York
|
-$287K |
| 2 |
SIM
Spark Investment Management
New York
|
-$147K |
| 3 |
Weiss Multi-Strategy Advisers
New York
|
-$97.6K |
| 4 |
Perceptive Advisors
New York
|
-$78.6K |
| 5 |
TI
Telemetry Investments
New York
|
-$72K |
ADMA Hedge Fund Activity: Q4 2016 in Review
18 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q4 2016, worth a combined $48M — down 30% from $68.7M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ADMA and 0 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $50.8K. The largest seller was Iguana Healthcare Management, cutting an estimated $287K.
- 18 institutional investors held ADMA Biologics (ADMA) as of Q4 2016, down from 19 in Q3 2016.
- Funds reported $48M of ADMA Biologics stock for Q4 2016, down 30% quarter-over-quarter.
- 0 funds opened new ADMA Biologics positions in Q4 2016 and 1 closed out, a net change of -1 holder.
- The largest ADMA Biologics buyer in Q4 2016 was Vanguard Group, an estimated $50.8K added.
- The largest ADMA Biologics seller in Q4 2016 was Iguana Healthcare Management, an estimated $287K sold.
Based on aggregated 13F filings for Q4 2016.